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Summary
Tamoxifen has been a mainstay of adjuvant therapy for breast cancer for many years. We sought to determine if
genetic variability in the tamoxifen metabolic pathway influenced overall survival in breast cancer patients treated
with tamoxifen. We examined functional polymorphisms in CYP2D6, the P450 catalyzing the formation of active
tamoxifen metabolites, and UGT2B15, a Phase II enzyme facilitating the elimination of active metabolite in a
retrospective study of breast cancer patients. We also examined whether the combination of variant alleles in
SULT1A1 and UGT2B15 had more of an impact on overall survival in tamoxifen-treated patients than when the
genes were examined separately.
We conducted a retrospective study using archived paraffin blocks for DNA extraction and data from pathology
reports and hospital tumor registry data for information on clinical characteristics, treatment, and outcomes (162
patients receiving tamoxifen and 175 who did not). Genotypes for CYP2D6 and UGT2B15 were obtained and Cox
proportional hazards modeling was performed.
After adjusting for age, race, stage of disease at diagnosis, and hormone receptor status, we found no significant
association between CYP2D6 genotype and overall survival in either group of breast cancer patients. Tamoxifen-
treated patients with UGT2B15 high activity genotypes had increased risk of recurrence and poorer survival. When
UGT2B15 and SULT1A1 ‘at-risk’ alleles were combined, women with two variant alleles had significantly greater
risk of recurrence and poorer survival than those with common alleles. These studies indicate that genetic variation
in Phase II conjugating enzymes can influence the efficacy of tamoxifen therapy for breast cancer.
Introduction
For over two decades, tamoxifen has been the gold
standard of endocrine therapy for estrogen receptor-
positive breast cancer [1], and its use has contributed to
the decline in breast cancer mortality. Analysis per-
formed by the Early Breast Cancer Trialist’s Collabo-
rative Group in 1998 demonstrated that breast cancer
patients treated with 5 years of tamoxifen had a 47%
reduction in recurrence of disease after 10 years of
follow-up and treatment was also associated with a
47% reduction in the occurrence of contralateral breast
cancer [2]. Tamoxifen has mixed estrogenic and
antiestrogenic properties; it is antiestrogenic in breast
tumors [1], while the estrogenic properties are respon-
sible for preservation of bone mineral density in post-
menopausal women [3,4], decreasing low-density
lipoprotein cholesterol [5,6] and lowering the risk of
myocardial infarction [7].
Competition by tamoxifen and its metabolites with
estradiol for occupancy of the estrogen receptor, thus
blocking estradiol-mediated cellular proliferation, is
considered to be one of the major mechanisms of
tamoxifen’s pharmacological action. The metabolism of
tamoxifen is complex, with tamoxifen undergoing
both oxidative and conjugative reactions. In the
liver, tamoxifen is converted to its major metabolite,
N-desmethyltamoxifen, by cytochrome P450 3A4
(CYP3A4), but this metabolite has low affinity for the
estrogen receptor. Two minor metabolites of tamoxifen,
4-hydroxytamoxifen (4-OH-TAM) and 4-hydroxy-N-
desmethyltamoxifen (endoxifen) are produced in a
reaction primarily mediated by cytochrome CYP2D6
[8], although other P450s are capable of forming 4-OH
TAM. These metabolites have much greater affinity
for the estrogen receptor than either tamoxifen or
N-desmethyltamoxifen, and are considered to be the
active metabolites of tamoxifen [9,10]. CYP2D6 is
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highly polymorphic in humans, with over 70 allelic
variants described. However, the CYP2D6 ‘poor
metabolizer’ phenotype can be attributed to the presence
of five alleles [11], with the CYP2D6*4 allele being
common in Caucasians. It is possible that, given the role
of CYP2D6 in the production of 4-OH TAM and
endoxifen, genetic variation in this enzyme could
influence treatment outcomes.
4-OH TAM is a substrate for conjugation reactions
catalyzed by sulfotransferase isoform 1A1 (SULT1A1)
and UDP-glucuronosyltransferase isoform 2B15
(UGT2B15) [12]. Both of these enzymes have functional
genetic polymorphisms; the SULT1A1*2 variant allele is
associated with decreased catalytic activity [13,14] and
the UGT2B15 Asp85 Tyr(UGT2B15*1/*2) variant is
located within the putative substrate recognition site of
the enzyme and is associated with increased velocity of
reaction [15]. We have shown previously that the low
activity SULT1A1*2 variant was associated with sig-
nificantly poorer overall survival in breast cancer pa-
tients receiving tamoxifen [16]. Patients who were
homozygous for the variant SULT1A1*2 allele had an
almost threefold increase in hazard of death compared
to patients who were heterozygous or homozygous for
the SULT1A1*1 common allele. To test the specificity
of the association, the SULT1A1*2 genotype was also
examined in a group of patients whose therapies did not
include tamoxifen; there was no association between
SULT1A1 genotype and survival in this group. In light
of these findings, we sought to determine if polymor-
phisms in other tamoxifen-metabolizing enzymes, par-
ticularly CYP2D6, which produces the active
metabolites, and UGT2B15, which is involved in the
elimination of active metabolites, influenced overall
survival in the same study population. Additionally, we
examined the combined effects of UGT2B15 and
SULT1A1 genetic variation on therapeutic outcomes.
Patients and methods
Study Population
The study population has been previously described in
detail in [16]. Patients who received their first course of
adjuvant treatment for primary invasive breast cancer at
the Arkansas Cancer Research Center, University of
Arkansas for Medical Sciences (UAMS) between the
years 1985 and 1996 were identified from hospital tumor
registry records; patients with a prior history of cancer
were excluded from the study. Tumor registry records and
pathology reports were used to obtain information con-
cerning age, stage at diagnosis, hormone receptor status,
race, date and type of therapy received (chemotherapy,
radiotherapy, surgery, hormonal treatment) and follow-
up data. The final study population was comprised of a
total of 162 patients who received tamoxifen and 175 who
did not receive hormonal therapy. The study protocol was
approved by the Institutional Review Board of UAMS.
DNA extraction and genotyping
Paraffin-embedded archived tissues were used as a
source of DNA for genotyping. A block containing
normal lymph nodes was selected if available; if normal
lymph nodes were not available, a block containing
other tissue noted as histologically normal was used.
Sections (50-lm) were cut from a paraffin block con-
taining normal tissue, the tissue was deparaffinized and
DNA was extracted using a commercially available kit
(Qiagen, Valencia, CA), as described previously [17].
Cytochrome P 450 2D6 (CYP2D6) taqman allelic
discrimination assay
Patients were genotyped for CYP2D6*3, CYP2D6*4
and CYP2D6*6 polymorphisms using the Applied Bio-
systems’ Taqman Allelic Discrimination Assay
according to the manufacturer’s instructions. Briefly,
10 ng DNA was added to a 5 ll reaction containing
forward and reverse primers along with two allele spe-
cific labeled probes (one wild-type and one variant allele
specific). The PCR and fluorescence measurements were
performed using the ABI Prism 7900HT sequence
detection system.
UGT2B15 genotype determination
An overlapping, bidirectional PCR assay to simulta-
neously amplify specific UGT2B15 alleles was developed
based on the Bi-PASA method of Liu et al. [18]. The
region flanking the polymorphic base pair was amplified
in a PCR reaction using outer primers as reported by
Levesque et al. [15] (UGT2B15 forward primer: 50-G
ACTGTGTTGACATCTTCGGCTTCT-30; UGT2B15
reverse primer: 50-CCAGTAGCTCACCACAGGGAT
TAAG-30). In addition to the outer primers, the PCR
reaction incorporates allele specific inner primers that
amplify products in different directions, producing dif-
ferent size products depending on the identity of the
polymorphic base. The inner allele specific primers were
forward: 50-GGGGCGGGGCCTACATCTTTAACT
AAAAATG-30 and reverse: 50-CGGGGCGGGGCA
GAAGAGAATCTTCCAAATA-30. These primers
incorporate GC rich tails that allow a switch from low
efficiency priming with genomic DNA as template, to
high efficiency amplification using previously amplified
PCR product as template. The amplification was per-
formed in a 50 ll volume containing 100 ng of genomic
DNA. 200 lM of each dNTP, 1 PCR buffer
(Promega), 2.5 mM MgCl2, 0.25 lM outer primers,
0.5 lM inner forward primer, 1.0 lM reverse inner
primer, 2.5 units Taq polymerase and 500 ng Taq-Start
antibody. After initial denaturation at 95 C for 4 min,
the samples were subjected to 35 cycles of 95 C for 30 s,
60 C for 30 s and 72 C for 30 s, followed by a final
extension step of 7 min at 72 C. Products of the PCR
reaction were detected by electrophoresis on a 4%
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Metaphor agarose gel and visualized by ethidium bro-
mide staining and UV transillumination.
Statistical analysis
We first evaluated relationships between patient and
tumor characteristics by genotype using v2 test. Survival
time was calculated as the time from diagnosis to death
or to the last contact date for living subjects. For anal-
ysis of disease-free survival, time from disease-free date
to recurrence, death, or last follow-up was calculated.
Person-years were calculated as the sum of survival
times for all subjects within a group. Crude associations
between genotypes for CYP2D6, UGT2B15, and
SULT1A1 and overall survival and recurrence-free
survival were evaluated using Kaplan–Meier survival
function with log-rank tests. Both heterozygote and
homozygote variant genotypes were assessed separately
in relation to the referent common genotype. Relative
risks were estimated by calculating hazard ratios (HR)
from Cox proportional hazard models. The final model
was adjusted for age, stage with node status at diagnosis,
race, ER status, and PR status. To examine the joint
effects of genotypes, we created dummy variables,
combining genotypes for UGT2B15 and SULT1A1,
using data on SULT1A1 that was previously reported
[16]. Analyses were conducted using SAS version 8.2.
Results
We obtained normal tissue samples and complete
baseline information for 165 eligible study subjects who
had received adjuvant tamoxifen therapy, and for 172
who had not been treated with tamoxifen. The charac-
teristics of the study population are presented in Table 1
and have been described in detail elsewhere [16]. When
characteristics were considered according to CYP2D6,
UGT2B15 or SULT1A1 genotype, there was no influ-
ence of genotype on patient characteristics. Genotype
frequencies did not differ by race. Genotype frequencies
for CYP2D6*4 were 0.15 for both races. Genotype fre-
quencies for UGT2B15*2 were 0.47 for Caucasians and
0.49 for African–Americans and genotype frequencies
for SULT1A1*2 were 0.35 for Caucasians and 0.33 for
African–Americans.
Since other CYP2D6 alleles (*3 and *6) were
infrequent in our study population, we performed our
analyses for one or more CYP2D6*4 variant alleles
compared to common alleles. After adjusting for age,
stage of disease, ethnicity and hormone receptor sta-
tus, Cox proportional hazards modeling showed no
association between CYP2D6*4 genotype and overall
survival of breast cancer patients receiving tamoxifen
(Hazard ratio (HR) ¼ 0.77, 95% CI 0.32–1.81,
Table 2). When the same analysis was performed for
the group of patients whose therapy did not include
tamoxifen, there was also no association between
CYP2D6 genotype and overall survival (HR ¼ 0.79,
95% CI 0.42–1.26). We also considered the association
between progression-free survival and CYP2D6 geno-
type in tamoxifen-treated patients. After excluding 11
patients who were never disease-free, there was no
association between recurrence of disease and
CYP2D6 genotype in tamoxifen-treated patients
(HR ¼ 0.67, 95% CI 0.33–1.35) or patients whose
therapy did not include tamoxifen (HR=0.69, 95% CI
0.40–1.18, Table 2).
When UGT2B15 genotype was considered, there was
no significant association between genotype and survival
in either the patient group receiving tamoxifen or the
group whose therapy did not include tamoxifen
(Table 3). When recurrence of disease was examined
according to UGT2B15 genotype, there was a
Table 1. Demographic information and pathological characteristics of
study participants and distributions of characteristics
n(n=337) %
Age at Diagnosis
<50 year 139 (41)




Stage with node status
1 106 (31)
2 negative 71 (21)










Chemo only 98 (29)
Radiation only 21 (6)
Chemo/radiation 53 (16)







Cancer cause death 61 (61)




Recurrence or death 84 (25)
Never disease free 10 (3)
Median survival year 4.58 year
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non-significant trend toward increased recurrence of
disease with increasing numbers of UGT2B15*2 alleles
(HR=1.56, 95% CI 0.68–3.61 for UGT2B15*1/*2 and
HR=2.27, 95% CI 0.82–6.28 for UGT2B15*2*2,
ptrend ¼ 0.11). In patients who did not receive tamox-
ifen, there was no evidence of a trend associated with
increasing numbers of UGT2B15*2 alleles and recur-
rence of disease (Table 3).
Table 2. Overall and progression-free survival of breast cancer patients according to CYP2D6 Genotype
Genotype Cases Deaths Person-years Deaths/person-years HRa(95% CI)
Overall survival
Tamoxifen 162 34
Cyp2d6 wt/wt 114 27 593 0.046 1 (Ref )
Cyp2d6 *4/*4 + *4/wt 48 7 253 0.028 0.77 (0.32–1.81)
ptrend = 0.51
No tamoxifen 175 66
Cyp2d6 wt/wt 126 48 596 0.080 1 (Ref )




Cyp2d6 wt/wt 112 38 524 0.073 1
Cyp2d6 *4/*4 + *4/wt 48 10 524 0.019 0.67 (0.33–1.35)
ptrend = 0.19
No tamoxifen 166 71
Cyp2d6 wt/wt 120 53 480 0.110 1
Cyp2d6 *4/*4 + *4/wt 46 18 240 0.075 0.69 (0.40–1.18)
ptrend = 0.19
aHRs for fully adjusted model: age, stage with node status at diagnosis, race, ER status, and PR status.
bEleven subjects were excluded because they were never disease-free.
Table 3. Overall and progression-free survival of breast cancer patients according to UGT2B15 Genotype





UGT2B15*1/*1 32 5 159 0.032 1
UGT2B15*1/*2 108 24 575 0.042 1.19 (0.44–3.22)
UGT2B15*2/*2 25 5 127 0.040 1.48 (0.42–5.27)
ptrend = 0.55
No Tamoxifen 172 66
UGT2B15*1/*1 36 14 187 0.075 1
UGT2B15*1/*2 110 43 552 0.078 1.15 0.62–2.12




UGT2B15*1/*1 32 7 147 0.041
UGT2B15*1/*2 106 33 511 0.039 0.61–3.12
UGT2B15*2/*2 25 9 112 0.045 0.70–5.11
ptrend = 0.11
No Tamoxifen 164 70
UGT2B15*1/*1 33 12 161 0.05
UGT2B15*1/*2 106 48 448 0.107 0.70–2.49
UGT2B15*2/*2 25 10 103 0.097 0.46–2.60
ptrend = 0.63
aHRs for fully adjusted model: age, stage with node status at diagnosis, race, ER status, and PR status.
bTen subjects were excluded because they were never disease-free; genotype data was missing for one subject.
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Since SULT1A1 and UGT2B15 have overlapping
substrate specificity for 4-OH TAM, and both are
Phase II detoxification enzymes, we examined combi-
nations of variant alleles to determine if there was an
additive effect with the genotypes and outcomes from
tamoxifen therapy. Tests for statistical interaction
between genotypes showed no interaction between
SULT1A1 and UGT2B15 in either the group receiving
tamoxifen (p ¼ 0:56) or those not receiving tamoxifen
( p ¼ 0:58). Earlier studies from our laboratory have
shown that enzymatic activity does not differ between
SULT1A1*1/*1 and SULT1A1*1/*2, while enzymatic
activity associated with SULT1A1*2/*2 is significantly
lower than that associated with the other two genotypes
[14]. Therefore, the referent category included
SULT1A1*1/*1 and SULT1A1*1/*2 in combination
with UGT2B15*1/*1 genotype. Genotypes were
assigned to the two variant category if they contained
SULT1A1*2/*2 in combination with UGT2B15*1/*2 or
UGT2B15*2/*2. All other possible allele combinations
were categorized as possessing one variant allele. When
overall survival was considered in the tamoxifen-treated
patients, there was a significant trend toward decreased
overall survival with increasing numbers of variant
alleles (HR=1.13, 95% CI 0.37–3.44 for one variant
and HR=4.40, 95% CI 1.17–16.55 for two variants,
ptrend ¼ 0.03, Table 4), although sample size was small,
resulting in unstable risk estimates. There was no effect
of numbers of variant alleles in patients whose therapy
did not include tamoxifen (HR=1.08, 95% CI 0.56–2.07
for one variant and HR ¼ 0.84, 95% CI 0.29–2.43 for
two variant alleles.
The Kaplan–Meier function for survival by com-
bined UGT2B15 and SULT1A1 genotypes is shown in
Figure 1A for tamoxifen-treated patients and Fig-
ure 1B for patients not receiving tamoxifen. The pro-
portion surviving at 5 years among tamoxifen-treated
patients was 0.88 (95% CI 0.81–2.47) for those with
one variant allele and 0.60 (95% CI 0.33–1.24) in the
group with two variant alleles ( p=0.003). There was
no difference in survival according to variant genotype
among patients who were not treated with tamoxifen;
the proportion of patients not treated with tamoxifen
who were alive at 5 years was 0.61 (95% CI 0.52–
1.62) for one variant allele, and 0.78 (95% CI 0.57–
1.90) for two variants ( p ¼ 0:81). When the group of
Table 4. Overall survival of breast cancer patients according to UGT2B15 and SULT1A1 Genotypes
Genotype Cases Deaths Person-years Death/person-years HRa(95% CI)
Overall survival
Tamoxifen 160 34
Both referentb 23 4 122 0.033 1
1 variant allelec 121 23 652 0.035 1.13 (0.37–3.44)
2 variant allelesd 16 7 67 0.104 4.40 (1.17–16.55)
ptrend = 0.03
No tamoxifen 171 65
Both referent 31 12 159 0.076 1
1 variant allele 124 48 575 0.084 1.08 (0.56–2.07)




Both referent 23 6 111 0.054 1
1 variant allele 120 36 585 0.062 1.54 (0.62–3.82)
2 variant alleles 15 7 56 0.125 3.79 (1.18–12.15)
ptrend = 0.03
No tamoxifen 163 69
Both referent 28 10 147 0.068 1
1 variant allele 119 52 511 0.102 1.25 (0.63–2.51)
2 variant alleles 16 7 112 0.063 1.31 (0.50–3.45)
ptrend = 0.35
aHRs for fully adjusted model: age, stage with node status at diagnosis, race, ER status, and PR status.
bBoth referent: SULT1A1*1/*1:UGT2B15*1/*1or SULT1A1*1/*2:UGT2B15*1/*1.
c1 variant: SULT1A1*2/*2:UGT2B15*1/*1; SULT1A1*1/*1:UGT2B15*2/*2; SULT1A1*1/*1:UGT2B15*1/*2; SULT1A1*1/*2:UGT2B15*
1/*2; SULT1A1*1/*2:UGT2B15*2/*2.
dTwo variants: SULT1A1*2/*2:UGT2B15*1/*2; SULT1A1*2/*2:UGT2B15*2/*2.
eTen subjects were excluded because they were never disease-free; genotype data was missing for one subject.
*SULT1A1 genotype data was missing for two tamoxifen-treated subjects and four subjects who did not receive tamoxifen.
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women who did not receive tamoxifen was restricted
to patients with ER positive tumors (n ¼ 82), there
was also no survival difference according to UGT2B15
and SULT1A1 genotype in this subgroup ( p ¼ 0:44).
When progression free survival was considered, Kap-
lan–Meier survival function showed a significant effect
on numbers of variant alleles on recurrence of disease
(Figure 2a). The proportion of patients free of pro-
gression at 5 years was 0.78 (95% CI 0.69–2.14) for
those with one variant allele and 0.50 (95% CI 0.22–
0.93) for two variants ( p ¼ 0.05). In the patient group
not receiving tamoxifen (Figure 2b), the proportion of
patients free of progression at 5 years was 0.53 (95%
CI 0.44–1.38) with one variant allele and 0.57 (95%
CI 0.31–1.18) for patients with two variant alleles
( p ¼ 0:74). The addition of UGT2B15 genotype to the
model produced a significant change of log likelihood
ratio, compared to a model with SULT1A1 genotype
alone ( p ¼ 0:01).
Discussion
A previous study from our laboratory demonstrated
that a common genetic polymorphism in SULT1A1, a
Phase II enzyme catalyzing the sulfation of 4-OH TAM,
was associated with poorer overall survival in breast
cancer patients receiving tamoxifen therapy [16]. In the
current study, and using the same study population as
the previous study, we demonstrated that genetic vari-
ation in the Phase II enzymes, SULT1A1 and
UGT2B15, alone or in combination was associated with
overall survival and recurrence of disease. In contrast,
genetic variation in CYP2D6, which catalyzes the Phase
I metabolism of tamoxifen to produce endoxifen and
4-OH TAM, had no apparent effect on overall survival
or recurrence of disease in tamoxifen-treated patients.
The majority of breast cancers occur in postmeno-
pausal women [19] whose tumors express the estrogen
and/or progesterone receptors [1,20,21] and tamoxifen
Figure 1. (a) O gdverall survival of breast cancer by combined UGT2B15 and SULT1A1 genotypes [35]. Patients receiving tamoxifen therapy;
(b) patients not receiving tamoxifen as part of their treatment for breast cancer.
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has been a mainstay of endocrine therapy for these pa-
tients for more than two decades. While the presence of
ER and/or PR is a good marker for patients likely to
benefit from antiestrogen therapy, not all patients who
fall into the same category of receptor expression have
the same degree of response to therapy. These differ-
ences in response are likely due, in part, to the individual
biochemistry of the patient and may be explained by the
contribution of genetic variation in metabolism (i.e.
pharmacogenetics). The influence of genetic variation on
response to drug therapy has long been recognized, but
until recently, studies on the role of pharmacogenetics in
relation to tamoxifen therapy have been lacking.
Several P450s are capable of producing 4-OH TAM
while CYP2D6 has been shown to play the dominant
role in the production of endoxifen, which is now
considered to be the predominant active metabolite of
tamoxifen since its pharmacological properties are
equivalent to that of 4-OH TAM and its plasma con-
centrations are eight-fold higher than that of 4-OH
TAM [10,22–24]. This metabolite is also produced by
CYP2D6, and genetic variation in CYP2D6 has been
shown to modulate plasma levels of endoxifen [24].
Therefore, genetic variation in CYP2D6 could be ex-
pected to influence efficacy of tamoxifen therapy. The
CYP2D6*3 and CYP2D6*6 variants were rare in our
study population (five individuals heterozygous for
CYP2D6*3 and three individuals heterozygous for
CYP2D6*6), therefore we were unable to analyze the
contribution of these alleles in this study (data not
shown). When CYP2D6*4 was examined, there was no
detectable influence of this genotype on overall survival
or recurrence of disease in either the patients who re-
ceived tamoxifen therapy or those whose therapy did
not include tamoxifen. It is interesting to note that in all
subgroups, the CYP2D6*4 variant seemed to be asso-
ciated with decreased risk of death or recurrence. Since
none of the measures were statistically significant, the
Figure 2. (a) Progression-free survival of breast cancer by combined UGT2B15 and SULT1A1 genotypes [35]. Patients receiving tamoxifen
therapy; (b) patients not receiving tamoxifen as part of their treatment for breast cancer.
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relevance of these findings is unclear. However, the
study population was small and the polymorphism was
found at a frequency of 0.15 in this population. There-
fore, this study could be underpowered to detect the
contribution of CYP2D6 to overall survival in breast
cancer patients receiving tamoxifen, and these studies
should be repeated in a larger study. Additionally, no
information was available concerning concomitant
medications, so it is possible that the findings are
influenced by the patients receiving drugs that could
inhibit the activity of CYP2D6. Another limitation is the
fact that another CYP2D6 allele found commonly in
African–Americans but not Caucasians could have an
influence (25). Since only 20% of our study population
was African–American, we were unable to examine the
influence of this allele.
We also examined the contribution of genetic varia-
tion in UGT2B15 to overall survival and recurrence of
disease. UDP-glucuronosyltransferases (UGTs) are
Phase II detoxification enzymes that catalyze the trans-
fer of the glucuronyl moiety from uridine 50-diphosp-
hoglucuronic acid to functional groups of a wide variety
of endogenous and exogenous compounds, facilitating
their excretion from the organism. The UGT2B family
are products of separate genes whose isoforms prefer-
entially glucuronidate steroids and bile acids, in addition
to xenobiotics [26]. UGT2B15 catalyzes the biotrans-
formation of a number of steroid substrates and exog-
enous compounds, including 4-OH TAM [27]. The
UGT2B15*1/*2 polymorphism produces an amino acid
change at residue 85 from aspartate (D85 ) to tyrosine
(Y85), resulting in enzymes with similar Km values but
with the Vmax increased twofold in the case of the Y
85
(UGT2B15*2) variant (15). UGT2B15 has been identi-
fied as the major UGT involved in the glucuronidation
of the cis- isomer of 4-OH TAM. Early studies suggested
that this isomer might exhibit estrogen agonist action
[28,29], but more recent studies have shown that, in the
presence of estradiol, cis-4-OH TAM has a significant
antagonist effect, although this effect is lower than that
seen with the trans isomer [9,30,31]. It has also been
reported that the geometrical isomerization of trans-4-
OH TAM to cis-4-OH TAM is catalyzed by CYP1B1 in
an atypical P450 reaction [32]. However, when we
examined a functional genetic polymorphism (Leu432-
Val) in CYP1B1 in this study population, there was no
association with recurrence or survival in patients who
did and did not receive tamoxifen (data not shown),
indicating that isomerization does not substantially
influence the pharmacological properties of 4-OH TAM
or that the CYP1B1 polymorphism is not important
enough in influencing CYP1B1 enzyme activity to show
a difference. In this study, we found that the
UGT2B15*2 high activity allele was associated with a
non-significant ( p ¼ 0:11) increased recurrence of dis-
ease in the tamoxifen-treated patients, but not in those
whose therapies did not include tamoxifen. This finding
is as would be expected if an active metabolite was
rapidly eliminated due to hepatic metabolism and
excretion. UGT2B15 is expressed in the liver, where it is
in a position to rapidly eliminate 4-OH TAM via the
biliary system. The majority of tamoxifen and its
metabolites are excreted in the bile [22,23]. Since sulfate
conjugates of xenobiotics are mainly excreted in the
urine, and glucuronides with molecular weights of
greater than 350 are preferentially excreted in the bile,
this indicates that glucuronidation may be the major
excretory pathway. Therefore, increased glucuronida-
tion of 4-OH TAM in the liver would lead to more rapid
excretion of the active metabolite. Additionally,
UGT2B15 is also expressed in adipose tissue in levels
comparable to those found in other extrahepatic tissues
[33], where it could participate in the extrahepatic
metabolism of 4-OH TAM. Recently, it has been re-
ported that another UGT, UGT1A4, is capable of di-
rectly glucuronidating tamoxifen [34]; hence, it is
possible that genetic variation in UGT1A4 could play a
role in response to tamoxifen. However, the Km for this
reaction was relatively high (32.4 lM), and the relative
role of UGT1A4 in tamoxifen biotransformation re-
mains to be established in vivo. The Phase II metabolism
of endoxifen has not been specifically tested thus far, but
it is very unlikely that the absence of one methyl group
distant from the 4-hydroxy moiety would alter conju-
gation reactions catalyzed by UGT2B15 or SULT1A1.
Additionally, genetic polymorphisms in these enzymes
appear to influence efficacy of tamoxifen therapy, indi-
cating their involvement in the metabolism of endoxifen.
Since SULT1A1 and UGT2B15 both catalyze
Phase II conjugation reactions, and both have variant
alleles that are associated with overall survival/recur-
rence in patients treated with tamoxifen, we also con-
sidered whether the combination of the two variants
would have an effect on therapeutic outcomes. Individ-
uals who possessed both variant alleles had significantly
increased hazard of death compared to individuals with
two common alleles, and these effects were greater than
when the genes were examined separately. Likewise,
there was a significant trend toward recurrence of dis-
ease with both variant alleles. When SULT1A1 geno-
type was examined previously, it was the individuals
who were homozygous for the low activity variant who
had poorer overall survival. This finding was counter-
intuitive, if sulfation of 4-OH TAM is an excretory
pathway. The epidemiological findings suggest that
there is a unique mechanistic basis of the effect of sulf-
ation of 4-OH TAM other than excretion. Studies are
currently underway in our laboratory to elucidate the
role of SO4-TAM in breast tumors (manuscript in
preparation). However, if rapid sulfation is beneficial,
and rapid glucuronidation is deleterious, then these
variant alleles might be expected to have additive
effects. In summary, we found that, while CYP2D6
genotype did not appear to influence therapeutic
outcomes, polymorphisms in UGT2B15 and SULT1A1
do appear to have an effect on overall survival and
recurrence of disease in patients treated with tamoxifen.
However, this preliminary report needs to be replicated
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in a larger, more homogeneous study population. Be-
cause the study population consisted of women with
various demographic and disease characteristics, who
received a number of varied and repeated treatments in
addition to tamoxifen, we are unable to determine if
effects differ by disease stage, race, etc. Nonetheless,
these findings indicate that genetic variability could
provide an explanation for therapeutic failures.
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